Prostate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenital tract, are mucosal-associated invariant T (MAIT) cells. MAIT cells express stereotyped T-cell receptors that recognize riboflavin metabolites derived from microbes presented by MR-1. We evaluated the number, phenotype and function of circulating MAIT cells, alongside two other innate-like T (ILT) -cell subsets, in men with prostate cancer and age- and sex-matched controls. MAIT cells in men with prostate cancer circulated at similar frequencies to controls, but their cytokine production and proliferation was impaired. In contrast, the function of two other ILT-cell populations (natural killer T-cells and Vg9Vd2 T-cells) was not impaired. In both patients and controls, MAIT cells expressed high levels of the immune checkpoint molecule PD-1 at rest, while upregulation of PD-1 in response to the MR-1 ligand 5-amino-6D-ribitylaminouracil (5-A-RU) was greater in patients. 5-A-RU also induced upregulation of PD-L1 and -L2 RNA in primary mononuclear cells. We confirmed that circulating MAIT cell number and function were preserved before and during anti-PD1 therapy with pembrolizumab in a cohort of patients with melanoma. In vitro, 5-A-RU enhanced mononuclear cell cytotoxicity against the PD-L1 positive prostate cancer cell line PC3 in an MR-1-dependent manner. Addition of pembrolizumab enhanced this cytotoxicity, and was associated with increased MAIT cell expression of CD107a and IFN-γ. We conclude that prostate cancer is associated with MAIT-cell dysfunction, and that this might be overcome through the application of potent MR-1 ligands with PD-1...
INTRODUCTION

Globally, prostate cancer is the sixth leading cause of cancer death among men, accounting for 359,000 deaths annually, a figure that is predicted to double over the next 20 years (1). Prostate cancer cells express tissue-specific antigens, which are potential targets for immunotherapies, including tumor vaccines or T-cell redirection (2, 3). However, late-phase clinical trials aimed at vaccinating against prostate-specific antigens have disappointed, with only Sipuleucel-T (an autologous dendritic cell therapy directed against prostatic acid phosphatase) demonstrating a statistically significant survival benefit (4). A role for checkpoint blockade immunotherapy in the treatment of prostate cancer is yet to be established, with little or no benefit of anti-CTLA-4 and/or anti-PD-1 therapies (5–11), possibly due to relatively low mutational burden and limited T-cell infiltration (12).

Innate-like T (ILT) -cells employ stereotyped T-cell receptors (TCRs) to recognize non-peptide antigens presented by molecules other than classical MHC, and together constitute a significant fraction of circulating T-cells. ILT-cells exhibit potent cytokine production and cytotoxicity, and their lack of MHC restriction means they can be specifically stimulated by conserved ligands, irrespective of patient tissue type (13). An ILT-cell population designated mucosal-associated invariant T (MAIT) -cells is especially prevalent in humans, alone constituting up to 10% of circulating human T-cells (14). MAIT-cells specifically recognize riboflavin metabolites produced by microbes presented on the molecule MR-1. MAIT-cells have been detected in the urogenital tract (15), and appear to be involved in immune responses to urinary pathogens (16, 17). Notably E. coli, a common cause of urinary tract infection (18), is well recognized to activate MAIT-cells (19) and MAIT-cell dysfunction has been associated with recurrent urinary tract infection (20). Furthermore, transcriptomic analysis indicates the presence of MAIT-cells within prostate tissue, and suggests that infiltration of MAIT-cells into prostatic adenocarcinoma is associated with a favorable prognosis (21).

Dysfunction of T-cells, and ILT-cells in particular, has been described in a number of malignancies, and might limit the efficacy of cancer immunotherapies. For example, a numeric and functional deficit of natural killer T (NKT) cells, a minor ILT-cell population in humans, has been described in patients with prostate cancer (22). However, another ILT-cell subset known as Vδ2+ gamma-delta T-cells, which recognize phosphoantigens, are numerically preserved in peripheral blood and present in tumour tissue in men with prostate cancer (23). This research aimed to determine the number and function of MAIT-cells in men with prostate cancer, and to explore their potential use for immunotherapy of prostate tumors. We report that circulating MAIT-cell numbers are preserved in prostate cancer, but that they exhibit impaired cytokine production and proliferative capacity upon specific stimulation, associated with enhanced expression of PD-1. We find that a potent MAIT-cell agonist can elicit MR-1-dependent lysis of a prostate cancer cell line, and that this is enhanced by PD-1 blockade. Our findings have implications for the rational design of immunotherapies that exploit MAIT-cells.

Keywords: prostate cancer, mucosal-associated invariant T cells, MR1 protein, PD-1 protein, human, pembrolizumab, natural killer T cells, gamma delta T cells

MATERIALS AND METHODS

Human Samples

Ethical approval to use peripheral blood mononuclear cells (PBMCs) from healthy volunteers was provided by Victoria University of Wellington Human Ethics Committee (Ref: 20957) and approval to use patient and healthy control PBMCs was obtained from the University of Otago Ethics Committee (Ref: H15/114). Departmental research governance approval to recruit patients from Wellington Blood and Cancer Centre was sought and provided by the Clinical Research Unit at Capital & Coast District Health Board. In consideration of Te Tiriti o Waitangi (The Treaty of Waitangi), consultation with local iwi (tribes) via the Research Advisory Group Māori was undertaken (Ref: RAG-M 2015/413).

Healthy volunteers were recruited from Victoria University of Wellington. Study participants with cancer were recruited from oncology and/or urology clinics in the Wellington region, and healthy controls were referred by participants with cancer. Participant eligibility was assessed through a written questionnaire. Potential participants were excluded from the study if they were unable to provide a blood sample, were diagnosed with HIV or were taking immunosuppressant medication (not including cancer patients receiving chemotherapy). Those eligible to donate provided written informed consent.

Peripheral venous blood was drawn into EDTA vacuum tubes (BD) and PBMCs isolated via density gradient centrifugation using Lymphoprep (Axis-Shield). All PBMC samples were cryopreserved at -180°C in liquid nitrogen prior to batch assay analysis.

Flow Cytometry

PBMCs were stained with fluorescent labelled antibodies, including CD3-BV510 (OKT3), CD4-BUV395 (SK3), CD8-PerCP-Cy5.5 (SK1), CD14-APC-Cy7 (63D3), CD19-BV785 or APC-CY7 (H1B19), CD107a-BV421 (H4A3), CD137-BV421 (4B4-1), CD161-FITC (HP-3G10), CD223-PE (11C3C65), CD274-PE (29E.2A3), CD279-BV421 or BV711 or PE (EH12.2H7), TCR-Vγ24α18-APC (6B11), TCR-Vα7.2-BV605 (3C10), TCR-Vγ9-PE (B3), TCR-Vδ2-BV711 (B6), Ki67-PE (B56). The stained cells were characterized on the LSR II flow cytometer (Becton-Dickinson) and analysis performed using FlowJo software (V.10.7.1, Becton Dickinson).

Relative
fluorescence intensity (RFI) was calculated from the mean fluorescence intensity (MFI) as:

\[ RFI = \frac{(MFI_{\text{stimulated}} - MFI_{\text{unstimulated}})}{MFI_{\text{unstimulated}}} \]

**ILT-Cell Functional Analyses**

In all assays MAIT-cells were identified as TCR-Vα7.2+CD161+ CD3−CD19− cells, and NKT and Vγ9Vδ2 T-cells were identified as TCR-Vα24I±I±CD3−CD19+ and TCR-Vγ9+TCR-Vδ2+ CD3−CD19− cells, respectively. MAIT-cells were stimulated with 5-Amino-6D-Ribitylaminouracil combined 1:1 with methyl-glyoxal immediately prior to use at a final concentration of 1 μM (5-A-RU/MG, Ferrier Institute, Lower Hutt, New Zealand). Vγ9Vδ2T and NKTs were stimulated with 1 μM disodium pamidronate (Hospira Australia Pty Ltd) and 200 nM α-galactosylceramide (α-GalCer, Ferrier Institute, Lower Hutt, New Zealand), respectively. Before use 5-A-RU was reconstituted from lyophilized powder in DMSO, diluted in PBS and stored at -20°C. MG, disodium pamidronate and α-GalCer were all stored at 4°C prior to use.

PBMCs were cultured with the above ILT-cell agonists and cell culture supernatant aspirated after 72-hours prior to the addition of 50 IU/mL interleukin-2 (IL-2, Sigma-Aldrich) to supplement T-cell growth. Cell culture supernatant cytokine analysis was performed using a Human Th1/Th2 Cytokine Assay (NanoString Technologies, Inc.). After a total of 7-days in culture at 37°C and 5% CO2, ILT-cell proportions and surface marker expression was analyzed by flow cytometry. ILT-cell expansion was determined per participant as the fold change in frequency relative to media control for each individual. In parallel, 10^5 PBMCs were cultured for 48 hours and detection of IFN-γ Enzyme Linked Immuno-Spots (ELISpots) was performed using the IFN-γ ELISpot kit (Mabtech, Sweden) as per manufacturer’s instructions.

**Gene Expression Analysis**

PBMCs from 6 healthy donors were cultured with 5-A-RU/MG or media control for 72 hours to specifically activate MAIT, NKT and Vγ9Vδ2T cells. RNA was extracted from these PBMCs using the Qiagen RNA mini kit (Qiagen) and purified using gDNA removal columns (Bio-Strategy) as per manufacturer’s instructions. The presence of RNA in samples was confirmed using the Nanodrop spectrophotometer (ThermoFisher Scientific PBMC). RNA was then applied to the PanCancer Immune nCounter Assay (NanoString Technologies, Inc.) according to the manufacturer’s instructions. The resulting raw data was normalized using nSolver (v3.0, NanoString Technologies, Inc.) Data was then log2-transformed and trimmed to exclude counts greater than 1.5 mean absolute deviations from the median value using RStudio (RStudio, Inc.). The data was then normalized using nSolver (nanoString Technologies, Inc.) Data was then log2-transformed and trimmed to exclude counts greater than 1.5 mean absolute deviations from the median value using RStudio (RStudio, Inc.).

**Statistical Analyses**

Statistical analyses of data were performed using Prism™ 8.3.0 (GraphPad Software, La Jolla, CA). Two-tailed P values were calculated in all analyses and a P value of < 0.05 was considered significant.

**RESULTS**

**Participant Characteristics**

We recruited 36 men with prostate cancer from local oncology and urology clinics. Median age was 70.5 years. Half of patients had active prostate cancer and elevated Prostate Specific Antigen (PSA). Almost half of patients had metastatic prostate cancer, a third with castrate-refractory disease. All patients had received treatment for their cancer, with two thirds ever having radiotherapy or androgen deprivation therapy (Table 1). We recruited 20 healthy male controls with a median age of 71 years.

**Impaired MAIT-Cell Function in Men With Prostate Cancer**

The frequency of circulating ILT-cells was determined by flow cytometry (Supplementary Figure 1). We observed no difference in the circulating frequency of NKT, MAIT or Vγ9Vδ2 T-cells or conventional CD4+ and CD8+ T-cells between patients with prostate cancer and healthy controls (Figure 1).

Having found similar ILT-cell numbers in patients compared to controls, we next assessed ILT-cell function. Patient and control PBMCs were cultured with ILT-cell agonists in both a 7-day proliferation assay and ELISpot assay. At the end of 7-day culture, the fold change of each ILT-cell type following agonist stimulation was determined by flow cytometry. When healthy controls were compared to patients with prostate cancer, a significant reduction in 5-A-RU/MG-induced MAIT-cell expansion was observed (Figure 2A). Trends towards reduced NKT and Vγ9Vδ2 T-cell proliferation were also observed but did not reach statistical significance (Figures 2B, C). We observed no difference in the number of IFN-γ-producing cells detected by ELISpot assay following ILT-cell stimulation between healthy controls and patients (Figures 2D–F). Corticosteroids have previously been described to impair MAIT cell function (24), however a comparison of 5-A-RU/MG stimulated MAIT proliferation and IFN-γ ELISpot formation between patients receiving steroids and those not demonstrated no statistically significant differences (Supplementary Figure 2).

ELISpot assays quantify the number of cytokine-producing cells, but not the amount of cytokine produced, or elicited, following MAIT-cell stimulation. Therefore, we used cytokine bead array to allow a comparison of cytokine quantity as opposed to cytokine spot forming unit frequency in the presence of various ILT-cell ligands. The production of IFN-γ, MIP-1α and MCP-1 in response to the MR-1 ligand 5-A-RU/MG was significantly impaired in patient PBMCs (Figure 3).
TABLE 1 | Characteristics of participants with prostate cancer.

| Characteristic | n (%) |
|----------------|-------|
| **PSA (ng/mL)** |       |
| Within normal limits (≤4) | 17 (47.2) |
| Elevated (>4) | 19 (52.8) |
| **Metastatic Disease** | 16 (44.4) |
| **Castrate Refractory** | 6 (16.7) |
| **Ever received Androgen Deprivation Therapy** | 24 (66.7)* |
| GnRH agonist | 19 (52.8) |
| AR antagonist | 3 (8.3) |
| Abiraterone | 6 (16.7) |
| **Current Systemic Corticosteroid use** | (9 25) |
| Prednisone | 7 (19.4) |
| Dexamethasone | 2 (5.6) |
| **Prior radiotherapy** | 23 (63.9) |
| External Beam | 16 (44.4) |
| Brachytherapy | 7 (19.4) |
| **Ever received Chemotherapy** | 6 (13.9) |

IQR, Interquartile Range. PSA, Prostate Specific Antigen. GnRH, Gonadotropin Releasing Hormone. AR, Androgen Receptor. *Values add to greater than total due some patients using multiple agents. Indented row titles and values represent a subset of the parent characteristic above, in bold.

FIGURE 1 | Circulating ILT-cell frequencies are preserved in men with prostate cancer. Flow cytometric analysis was used to determine the proportion of MAIT (A), NKT (B), Vγ9Vδ2T (C), CD4⁺ (D) and CD8⁺ (E) T-cells between men with prostate cancer and healthy male controls. Mann-Whitney test. N = 20 healthy controls, 36 men with prostate cancer. ns, no significance.
In contrast, in response to the NKT ligand α-GalCer and indirect Vγ9Vδ2 ligand, pamidronate, only MCP-1 production was significantly impaired in patients compared to controls (Figure 3). Association Between Impaired MAIT-Cell Function and PD-1 Having demonstrated impaired MAIT-cell proliferation and cytokine production in men with prostate cancer, we therefore characterized immune checkpoint molecule expression, which may influence MAIT-cell function. We used the NanoString PanCancer Immune panel to assess gene expression in PBMCs from 6 healthy donors stimulated with the MAIT-cell-specific agonist or vehicle. From this data we selected the expression of the 33 immune-associated inhibitory and stimulatory genes included in the panel for analysis. In response to 5-ARU/MG, we observed upregulation of the PD-1 ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2), but not PD-1 (PDCD1) itself, across donors (Figure 4A). IFN-γ can induce expression of PD-1 ligands, while suppression of T-cell proliferation and IFN-γ production by PD-1 signaling has been well-described (25). We assessed the PD-1 expression on MAIT-cells in unstimulated PBMCs, and found higher expression compared to non-MAIT T-cells (Figures 4B, C). Accordingly, MAIT-cells were significantly over-represented among the PD-1high fraction of total T-cells in both healthy controls and patients. There was no significant difference in the frequency of MAIT-cells within the PD-1high fraction between patients and healthy controls (Figure 4D).

Further, MAIT-cells from patients, but not healthy controls, significantly upregulated surface PD-1 following their stimulation with 5-A-RU/MG. When these groups were compared, we observed significantly greater upregulation of PD-1 on patient MAIT-cells (Figures 5A, B). To explore whether any relationship existed between proliferation and PD-1 upregulation, patients and healthy controls were divided into high and low responders on the basis of whether their proliferation in response to MAIT-cell agonist was above or below their group’s median proliferation, respectively. Patients, but not healthy controls, whose MAIT-cells underwent lesser proliferation in response to specific stimulation upregulated surface PD-1 to a greater extent (Figure 5C). Linear correlation of MAIT-cell proliferation versus MAIT-cell PD-1 Expression Intensity suggested a weak negative correlation between proliferation and PD-1 upregulation (Supplementary Figure 3; Spearman r = -0.3846, P-value = 0.0247).

Anti-PD-1 Does Not Alter MAIT-Cell Function Ex Vivo Having established that MAIT-cell dysfunction is associated with enhanced PD-1 expression in men with prostate cancer, we sought to assess the effect of PD-1 blockade on human MAIT-cells. On one hand, given the over-representation of MAIT-cells within the PD-1high fraction between patients and healthy controls (Figure 4D).

**FIGURE 2** | 5-A-RU/MG stimulated MAIT-cell proliferation, but not IFN-γ SFU, is impaired in men with prostate cancer. The proliferation of MAIT (A), NKT (B) and Vγ9Vδ2T (C) cells was measured at the end of 7 days in culture with stimuli as indicated and expressed as a fold change to media control. IFN-γ spot forming units (SFUs) determined by ELISpot assay are demonstrated for PBMCs cultured with 5-A-RU/MG (D), α-GalCer (E) and pamidronate (F). **P < 0.01, Mann-Whitney test. N = 20 healthy controls, 36 men with prostate cancer. ns, no significance.
among PD-1<sup>high</sup> T-cells (Figure 4D), pembrolizumab might deplete circulating MAIT-cells, and on the other hand it might enhance their function. As anti-PD-1 treatment is not approved for use in prostate cancer, we attempted to address this question in a cohort of 10 unresectable melanoma patients undergoing standard-of-care therapy with pembrolizumab. Men made up 80% of the patient group, 50% were receiving systemic steroids and no patients had received chemotherapy previously.

Comparing pre-treatment with post-pembrolizumab samples, we observed a reduction in PD-1 expression, but no change in the frequency of circulating MAIT-cells or of the surface expression of the activation marker CD137 (4-1BB) on MAIT-cells in unstimulated PBMCs (Figures 6A–C). We believe the reduction in the detection of surface PD-1 likely reflects steric hindrance by the presence of pembrolizumab on cells, as has been previously demonstrated (26), but we did not evaluate this further. After stimulation with 5-A-RU/MG, we did not find a difference in ex vivo proliferation or cytokine production by circulating MAIT-cells following pembrolizumab therapy, although we did observe greater upregulation of CD137 on stimulated MAIT-cells after pembrolizumab treatment (Figures 6D–G).

**Anti-PD-1 and MAIT Cell Activation Controls Prostate Cancer Growth In Vitro**

While therapeutic PD-1 blockade had little impact on the number or function of circulating MAIT-cells, we wished to establish whether anti-PD-1 could affect MAIT-cell function in the setting of tumour cells expressing PD ligands. To do so, we employed an impedance-based assay to assess cytotoxicity against the prostate cancer cell line PC3, which expresses PD-L1 (27). We found that healthy donor PBMCs suppressed growth of PC3 in response to 5-A-RU/MG, and that this suppression was MR-1-dependent (Figures 7A, B). Pre-treatment of healthy donor PBMCs with anti-PD-1 further enhanced 5-A-RU/MG suppression of PC3 growth (Figures 7C, D). Finally, when we treated PC3 cells with 5-A-RU/MG, then co-cultured with pembrolizumab or isotype control-treated healthy donor PBMCs, we found that a greater proportion of MAIT-cells, but...
FIGURE 4 | A MAIT-cell specific agonist upregulates PD-1 ligands, circulating MAIT-cells express high levels of PD-1 and MAIT-cells are over-represented among PD-1+ T-cells. Immune checkpoint genes significantly upregulated by PBMCs cultured with 5-A-RU/M3 are shown in (A). N = 6 healthy donors. Flow cytometric analysis was used to determine the surface expression of PD-1 on MAIT and Vα7.2 TCR+CD161+ Vα7.2 TCR+CD161+ T-cells in unstimulated PBMCs. Representative histograms (B) and surface PD-1 median fluorescence intensity (MFI) (C) are shown. The proportion of MAIT-cells within the PD-1+ and PD-1- fractions of PBMCs from healthy controls and men with prostate cancer is displayed in (D). N = 20 healthy controls (HC), 36 men with prostate cancer (PC). ns, no significance. **P < 0.01. ***P < 0.001. ND, non detectable. ns, no significance.
not non-MAIT cells or NK-cells, expressed the cytotoxicity-associated molecules CD107a and IFN-γ (Figures 7E, F).

**DISCUSSION**

Using samples from a cohort of men with prostate cancer and age- and sex-matched controls, we report that circulating MAIT-cells are numerically preserved in prostate cancer but exhibit impaired cytokine production and proliferative capacity in response to the MR-1 ligand 5-A-RU. We find that MAIT-cells express high levels of PD-1 at rest, that MAIT-cell PD-1 expression is enhanced by 5-A-RU, particularly in patients, and that 5-A-RU leads to upregulation of PD-L1 and PD-L2 RNA within mononuclear cells. We find that despite high MAIT-cell PD-1 expression, clinical exposure to the humanized anti-PD1 antibody pembrolizumab does not deplete circulating MAIT-cells. Finally, we report that 5-A-RU elicits MR-1-dependent lysis of a prostate cancer cell line by human PBMCs in vitro, and that this effect is enhanced by pembrolizumab, in association with increased MAIT-cell expression of the cytotoxicity-associated molecules CD107a and IFN-γ.

To our knowledge, this study is the first to describe MAIT-cell numbers and function in prostate cancer. As well as describing MAIT-cell dysfunction in patients, we associate this with enhanced PD-1 upregulation upon specific stimulation, and demonstrate that PD-1 blockade can lead to enhanced MAIT-cell cytotoxicity against a prostate cancer cell line in response to a MR-1 ligand. Moreover, in a separate cohort of patients with melanoma, we report that treatment with pembrolizumab does not deplete, nor impede the function of, MAIT cells.

Our patient cohort was of similar size to other clinical cohorts examining MAIT-cell number and function (28, 29), and we were careful to age- and sex-match the patient and control groups. However, the patients were not uniformly treated, and our sample size is insufficient to explore associations between disease stage or specific treatments on MAIT-cell number and function. The cross-sectional study design does not allow us to determine whether MAIT-cell dysfunction is involved in prostate cancer onset or progression or a consequence of prostate cancer therapies – longitudinal studies could provide insight into this.

We identified MAIT-cells as cells expressing the Vα7.2 TCR chain, CD161, and CD3. While this is considered one of the most reliable surrogate staining methods for human MAIT-cells, compared to MR1 tetramer staining, we may have overestimated CD4+ MAIT-cells, and our staining method would not have identified either MR1-restricted T-cells that do not use the Vα7.2 chain, or the small population of CD161-MAIT-cells (30, 31). The functional assays we report, such as cytokine production and cytotoxicity in response to 5-A-RU, are not affected by this limitation. We characterized only circulating MAIT-cells. It is plausible that MAIT-cells within the prostate tumor microenvironment differ in terms of number, cytokine profile or proliferative capacity. For example, Ling et al. reported a reduction in circulating MAIT-cells, but an increase in tumor-infiltrating MAIT-cells, in colorectal cancer (28).

Although MAIT-cells have not been previously studied in prostate cancer to our knowledge, they have been studied in other malignancies. Circulating MAIT-cell numbers were reduced in patients with esophageal cancer (29), whereas there is conflicting evidence in colorectal cancer (28, 32, 33). Reduced cytokine production, including of IFN-γ, by circulating and intra-tumoral MAIT-cells has been reported in patients with both colorectal (28, 32) and hepatocellular carcinoma (34), consistent with our own observation. Innate-like T-cells other than MAIT-cells have been studied in prostate cancer:

![FIGURE 5](image-url)
Tahir et al. described a functional NKT deficit and an inability to detect circulating NKTs in a small cohort of men with prostate cancer (22). In our larger patient cohort, we did not see a difference in circulating NKT numbers, although we observed an on-significant trend towards reduced NKT expansion. Normal circulating levels of Vd2 T-cells have previously been reported in prostate cancer (23), consistent with our own finding in the more specific Vg9Vd2 T-cell subset.

Clinical trials of immunotherapy with PD-1 blockade have had limited success in prostate cancer to date (7–9). A recent report found that higher MAIT-cell numbers and greater MAIT-cell expression of cytotoxicity-associated molecules predicted clinical response among patients receiving anti-PD-1 therapy for melanoma (35). In conjunction with our own finding that MAIT-cells are highly over-represented among PD-1 high T-cells, this raises the possibility that MAIT-cells are directly involved in clinical responses to therapeutic PD-1 blockade.

In keeping with their capacity to recognize microbial metabolites, MAIT-cells are present at high frequencies in barrier tissues (36), including in the urinary tract (16, 20). Although T-cell infiltration into prostate cancer is characteristically limited (37), the MAIT-cell-associated Vα7.2-Jα33 TCR transcript has been identified in human prostate tissue (15). Moreover, in an analysis of public datasets, gene expression signatures associated with MAIT-cells were identified in prostate cancer, correlated with MR-1 expression, and were associated with a favorable prognosis (21).

The most frequent human urinary tract pathogens, E. coli and Klebsiella species (38), produce riboflavin metabolites that result in potent MAIT-cell activation, and dysfunction of MAIT-cells has been described among patients with recurrent urinary tract infections (20). Intriguingly, in a mouse model of prostate cancer, the combination of a uropathic strain of E. coli (administered intraurethrally) with systemic anti-PD-1 therapy resulted in improved T-cell infiltration, prostate cancer regression and survival (39). In conjunction with our own finding that a potent MR-1 ligand and pembrolizumab can cooperate to enhance MR-1-dependent cytotoxicity against a prostate cancer cell line, this raises the possibility of rationally combining PD-1 blockade with prostate-directed (intraurethral

![FIGURE 6](https://example.com/figure6.png)

**FIGURE 6** | Pembrolizumab does not deplete MAIT-cells in vivo nor does it enhance MAIT-cell function ex vivo. The circulating frequency of MAIT-cells (A) and their surface expression of CD137 (B) and PD-1 (C) in unstimulated PBMCs was compared for patients with melanoma before and after their first dose of pembrolizumab. PBMCs were then cultured with 5-A-RU/MG for 7 days and the proliferation of MAIT-cells (D) and the upregulation of CD137 (E) and PD-1 (F) at the end of culture calculated. Mann-Whitney test. ns, no significance. *P < 0.05. **P < 0.01. No significant differences were observed for cytokines quantified in 72 hour culture supernatant for pre and post pembrolizumab samples (G). N, 10.
or transrectal) administration of MR-1 ligands. By recruiting, activating and de-repressing MAIT-cells, this combination might turn the cold prostate cancer microenvironment hot (37). In vivo assessment of this strategy would be necessary: although most mouse strains have few MAIT-cells compared to humans, xenograft models, or models based on the MAIT cell-rich CAST/EiJ mouse strain could be employed (16).

In conclusion, we identify normal numbers, but impaired function, of circulating MAIT-cells in patients with prostate cancer. We find that this MAIT-cell dysfunction is associated with enhanced PD-1 expression upon stimulation, and that the combination of a potent MR-1 ligand with PD-1 blockade enhances MR-1-dependent cytotoxicity against a prostate cancer cell line. Our findings support investigation of PD-1 blockade in combination with MAIT-cell stimulation for the treatment of prostate and other cancers.

![Data Availability Statement](image)

The RNA Nanostring data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (40) and...
are accessible through GEO Series accession number GSE184313 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE184313).

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Victoria University of Wellington Human Ethics Committee (Ref: 20957) and the University of Otago Ethics Committee (Ref: H15/114). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

E-MJ, SC, and RW designed experiments, applied for ethics, and collected and analysed the data. AA-H and ND assisted with assay troubleshooting, data acquisition and analysis. BL and JN provided oversight for ethics, experimental design and statistical analysis. E-MJ and RW wrote the manuscript and prepared the figures, which were reviewed by all authors prior to submission. All authors contributed to the article and approved the submitted version.

FUNDING

Funding for the above project was provided by the Prostate Cancer Foundation of New Zealand, the Health Research Council of New Zealand (14/502), the Wellington Division of the Cancer Society of New Zealand, and the Thompson Family Foundation.

ACKNOWLEDGMENTS

The authors would like to acknowledge the staff of the Wellington Blood & Cancer Centre for their assistance in obtaining venepuncture samples from patients with cancer, and Dr David Eccles for his assistance in bioinformatic and statistical analyses.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.748741/full#supplementary-material

REFERENCES

1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. *Eur Urol* (2020) 77:38–52. doi: 10.1016/j.eururo.2019.08.005
2. Fay EK, Graff JN. Immunotherapy in Prostate Cancer. *Cancers* (2020) 12:1752. doi: 10.3390/cancers12071752
3. Boeticher AN, Usman A, Morgans A, Vander Weele DJ, Sosman J, Wu JD. Past, Current, and Future of Immunotherapies for Prostate Cancer. *Front Oncol* (2019) 9:984. doi: 10.3389/fonc.2019.00984
4. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized Trial of Autologous Cellular Immunotherapy With Sipuleucel-T in Androgen-Dependent Prostate Cancer. *Clin Cancer Res* (2011) 17:4558–67. doi: 10.1158/1078-0432.CCR-10-3223
5. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipiplumab Versus Placebo After Radiotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer That had Progressed After Docetaxel Chemotherapy (CA184-043): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. *Lancet Oncol* (2014) 15:700–12. doi: 10.1016/S1470-2045(14)70189-5
6. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, Double-Blind, Phase III Trial of Ipiplumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. *J Clin Oncol* (2017) 35:40–7. doi: 10.1200/JCO.2016.15.1584
7. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer: Oncotarget (2016) 7:52816–7. doi: 10.18632/oncotarget.10547
8. Antonarakis ES, Poulatsis JM, Gross-Goupil M, Goh J, Ojamaa K, Holmes CJ, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. *J Clin Oncol* (2020) 38:395–405. doi: 10.1200/JCO.19.01638
9. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Eijadi S, et al. Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 Study. *Ann Oncol* (2018) 29:1807–13. doi: 10.1093/annonc/mdy232
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *N Engl J Med* (2012) 366:2443–54. doi: 10.1056/NEJMoa1200690
11. Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Initial Results From a Phase II Study of Nivolumab (NIVO) Plus Ipiplumab (IPI) for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC; CheckMate 650). *J Clin Oncol* (2019) 37:142–2. doi: 10.1200/JCO.2019.37.7_supp.142
12. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearey J, et al. Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade-Based Immunotherapy. *Science* (2018) 362(6411):eaar3593. doi: 10.1126/science.aar3593
13. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DR. The Burgeoning Family of Unconventional T Cells. *Nat Immunol* (2015) 16:1114–23. doi: 10.1038/ni.3298
14. Mori L, Lepore M, De Libero G. The Immunology of CD1- and MR1-Limited T Cells. *Annu Rev Immunol* (2016) 34:479–510. doi: 10.1146/annurev-immunol-032414-112008
15. Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, Tschumi A, et al. Parallel T-Cell Cloning and Deep Sequencing of Human MAIT Cells Reveal Stable Oligoclonal TCRbeta Repertoire. *Nat Commun* (2014) 5:3866. doi: 10.1038/ncomms4866
16. Cui Y, Franciszekiewicz K, Mburu YK, Mondot S, Le Bourhis L, Premel V, et al. Mucosal-Associated Invariant T Cell-Rich Congenic Mouse Strain Allows Functional Evaluation. *J Clin Invest* (2015) 125:4171–85. doi: 10.1172/JCI82424
17. Lacerda Mariano L, Ingersoll MA. The Immune Response to Infection in the Bladder. *Nat Rev Urol* (2020) 17:439–58. doi: 10.1038/s41585-020-0350-8
18. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. *Nat Rev Microbiol* (2015) 13:269–84. doi: 10.1038/nrmicro3432
19. Dias J, Sobkowiak MJ, Sandberg JK, Leansyah E. Human MAIT-Cell Responses to Escherichia Coli: Activation, Cytokine Production, Proliferation, and Cytotoxicity. *J Leukoc Biol* (2016) 100:233–40. doi: 10.1189/jlb.4TA0815-391RR
20. Terpstra ML, Remmerswaal EB, van Alderden MC, Weaver J, Sinnige MJ, van der Bom-Baylon ND, et al. Circulating Mucosal-Associated Invariant T
Cells in Subjects With Recurrent Urinary Tract Infections Are Functionally Impaired. *Immun Inflamm Dis* (2020) 8:80–92. doi: 10.1002/iid3.287.

21. Yao T, Shoosharti P, Haeryfar SM. Leveraging Public Single-Cell and Bulk Transcriptomic Datasets to Delineate MAIT Cell Roles and Phenotypic Characteristics in Human Malignancies. *Front Immunol* (2020) 11:1691. doi: 10.3389/fimmu.2020.01691.

22. Tahir SM, Cheng O, Shaulov A, Koerzuka Y, Bubley GJ, Wilson SB, et al. Loss of IFN-Gamma Production by Invariant NK T Cells in Advanced Cancer. *J Immunol* (Baltimore Md 1950) (2001) 167:4046–50. doi: 10.4049/jimmunol.167.7.4046.

23. Vella M, Coniglio D, Abrate A, Scalici Gesolfo C, Lo Preti E, Meraviglia S, et al. Characterization of Human Infiltrating and Circulating Gamma-Delta T Cells in Prostate Cancer. *Investig Clin Urol* (2019) 60:951–8. doi: 10.4111/icu.2019.60.2.91.

24. Hinks TS, Wallington JC, Williams AP, Djukanovic R, Staples KJ, Wilkinson TM. Steroid-Induced Deficiency of Mucosal-Associated Invariant T Cells in the Chronic Obstructive Pulmonary Disease Lung. Implications for Nontypeable Haemophilus Influenzae Infection. *Am J Respir Crit Care Med* (2016) 194:1208–18. doi: 10.1164/rcrm.201601-0002OC.

25. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 Blockade Enhances T-Cell Migration to Tumors by Elevating IFN-Gamma Inducible Chemokines. *Cancer Res* (2012) 72:5209–18. doi: 10.1158/0008-5472.CAN-12-1187.

26. Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B. Accurate Quantification of T Cells Expressing PD-1 in Patients on Anti-PD-1 Immunotherapy. *Cancer Immunol Immunother* (2018) 67:1845–51. doi: 10.1007/s00262-018-2244-7.

27. Martin AM, Nirschel TR, Nirschel CJ, Francia BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance. *Prostate Cancer Prostatic Dis* (2015) 18:325–32. doi: 10.1038/pcan.2015.39.

28. Ling L, Lin Y, Zheng W, Hong S, Tang X, Zhao P, et al. Circulating and Tumor-Infiltrating Mucosal Associated Invariant T (MAIT) Cells in Colorectal Cancer Patients. *Sci Rep* (2016) 6:20358. doi: 10.1038/srep20358.

29. Melo AM, O’Brien AM, Phelan JJ, Kennedy SA, Wood NAW, Veerapen N, et al. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. *Front Immunol* (2019) 10:1580. doi: 10.3389/fimmu.2019.01580.

30. Gherardin NA, Souter MN, Koay HF, Mangas KM, Seemann T, Stinear TP, et al. Human Blood MAIT Cell Subsets Defined Using MR1 Tetramers. *Immunol Cell Biol* (2018) 96(5):507–25. doi: 10.1111/icmb.12021.

31. Koay HF, Gherardin NA, Xu C, Seneviratna R, Zhao Z, Chen Z, et al. Diverse MR1-Restricted T Cells in Mice and Humans. *Nat Commun* (2019) 10(1):2243. doi: 10.1038/s41467-019-10198-w.

32. Sundström P, Ahlmanner F, Akkeu P, Sundquist A, Alsen S, Yrlid U, et al. Human Mucosa-Associated Invariant T Cells Accumulate in Colon Adenocarcinomas But Produce Reduced Amounts of IFN-Gamma. *Immunol (Baltimore Md 1950)* (2015) 195(7):3472–81. doi: 10.4049/jimmunol.1500258.

33. Rodin W, Sundström P, Ahlmanner F, Szepónik L, Zajt KK, Wettergren Y, et al. Exhaustion in Tumor-Infiltrating Mucosal-Associated Invariant T (MAIT) Cells From Colon Cancer Patients. *Cancer Immunol Immunother* (2021). doi: 10.1007/s00262-021-02939-y.

34. Duan M, Goswami S, Shi JY, Wu LJ, Wang YX, Ma JQ, et al. Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma. *Clin Cancer Res: An Off J Am Assoc Can Res* (2019) 25(11):3304–16. doi: 10.1158/1078-0432.CCR-18-3040.

35. De Biasi S, Gibellini L, Lo Tartaro D, Puccio S, Rabacchi C, Mazza EMC, et al. Circulating Mucosal-Associated Invariant T Cells Identify Patients Responding to Anti-PD-1 Therapy. *Nat Commun* (2021) 12(1):1669. doi: 10.1038/s41467-021-21928-4.

36. Amini A, Pang D, Hackstein CP, Klenerman P. MAIT Cells in Barrier Tissues: Lessons From Immediate Neighbors. *Front Immunol* (2020) 11:584521. doi: 10.3389/fimmu.2020.584521.

37. Vitkin N, Nersesian S, Siemens DR, Kotti M. The Tumor Immune Contexture of Prostate Cancer. *Front Immunol* (2019) 10:603. doi: 10.3389/fimmu.2019.00603.

38. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, et al. In Vitro and In Vivo Analysis of the Gram-Negative Bacteria-Derived Riboflavin Precursor Derivatives Activating Mouse MAIT Cells. *J Immunol (Baltimore Md 1950)* (2015) 194(10):4641–9. doi: 10.4049/jimmunol.1403224.

39. Anker JP, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-Faceted Immunomodulatory and Tissue-Tropic Clinical Bacterial Isoolate Potentiates Prostate Cancer Immunotherapy. *Nat Commun* (2018) 9(1):1591. doi: 10.1038/s41467-018-03900-x.

40. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI Gene Expression and Hybridization Array Data Repository. *Nucleic Acids Res* (2002) 30(1):207–10.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Jarvis, Collings, Authier-Hall, Dasyam, Lucy, Nacey, Painter, Delahunt, Herrmans and Weinkove. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.